Diéras, Véronique http://orcid.org/0000-0001-8094-4738
Bonnefoi, Hervé
Alba, Emilio
Awada, Ahmad
Coudert, Bruno
Pivot, Xavier
Gligorov, Joseph
Jager, Agnes
Zambelli, Stefania
Lindeman, Geoffrey J. http://orcid.org/0000-0001-9386-2416
Charpentier, Eric
Emmons, Gary T.
Garcia-Ribas, Ignacio
Paridaens, Robert
Verweij, Jaap
Clinical trials referenced in this document:
Documents that mention this clinical trial
Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: a phase II randomized open-label study with pharmacokinetics
https://doi.org/10.1007/s10549-019-05305-w
Funding for this research was provided by:
Sanofi
Article History
Received: 22 May 2019
Accepted: 28 May 2019
First Online: 6 June 2019
Compliance with ethical standards
:
: EC, GTE and IGR are current or former employees and have stock options of Sanofi. JG and JV have received remuneration and/or had an advisory/consultancy role for Sanofi. VD, EA, AA, JG, and JV have/had a consultancy/advisory role with and/or received remuneration from pharmaceutical companies other than Sanofi. All other authors declare no potential conflicts of interest (HB, BC, XP, AJ, SZ, GL, RP).
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.
: Informed consent was obtained from all individual participants included in the study.